Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$1.3 million.

  • Allogene Therapeutics' Change in Accured Expenses fell 57.04% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $478,000, marking a year-over-year increase of 112.40%. This contributed to the annual value of -$1.3 million for FY2024, which is 81.50% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Change in Accured Expenses of -$1.3 million as of FY2024, which was up 81.50% from -$6.8 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Change in Accured Expenses peaked at $18.7 million during FY2020, and registered a low of -$6.8 million during FY2023.
  • In the last 3 years, Allogene Therapeutics' Change in Accured Expenses had a median value of -$1.3 million in 2024 and averaged -$2.1 million.
  • Per our database at Business Quant, Allogene Therapeutics' Change in Accured Expenses soared by 194.85% in 2020 and then crashed by 490.11% in 2023.
  • Allogene Therapeutics' Change in Accured Expenses (Yearly) stood at $18.7 million in 2020, then tumbled by 80.50% to $3.7 million in 2021, then plummeted by 52.11% to $1.7 million in 2022, then plummeted by 490.11% to -$6.8 million in 2023, then surged by 81.50% to -$1.3 million in 2024.